SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
----------
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of Earliest Event Reported): August 26, 2002
ANTARES PHARMA, INC.
--------------------
(Exact Name of Registrant as Specified in Charter)
Minnesota 0-20945 41-1350192
--------- ------- ----------
(State or Other Jurisdiction (Commission (I.R.S. Employer
of Incorporation) File Number) Identification No.)
707 Eagleview Boulevard, Suite 414, Exton, PA 19341
---------------------------------------------------
(Address of Principal Executive Offices) (Zip Code)
Registrant's telephone number, including area code: (610) 458-6200
Not Applicable
-------------------------------------------------------------
(Former Name or Former Address, if Changed Since Last Report)
Item 5. Other Events.
Rule 10b5-1 Trading Plans
-------------------------
In connection with Rule 10b5-1 under the Securities Exchange Act of
1934, the Board of Directors of Antares Pharma, Inc. (the "Company") approved
amendments to the Company's insider trading policy to permit its officers and
directors to enter into written trading plans or arrangements for systematic
trading in the Company's securities. The Company has been advised that on August
26, 2002, Dr. Roger G. Harrison, the Company's Chief Executive Officer, entered
into a trading plan complying with Rule 10b5-1 and the Company's insider trading
policy. Pursuant to Dr. Harrison's Rule 10b5-1 trading plan, he has instructed
his broker to purchase up to $1,000.00 worth of shares of the Company's common
stock each week, commencing on September 10, 2002, subject to certain
conditions. Dr. Harrison may modify his trading plan under certain
circumstances, and he reserves the right to terminate the trading plan at any
time.
The Company anticipates that, as permitted by Rule 10b5-1 and the
Company's insider trading policy, some or all of its officers, directors and
other insiders may establish trading plans at some date in the future.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934,
the Registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.
Date: September 16, 2002 ANTARES PHARMA, INC.
By /s/ Roger G. Harrison
----------------------------
Roger G. Harrison
Chief Executive Officer